Trident Texofab Limited has formally notified the stock exchanges about an upcoming board meeting scheduled for February 12, 2026, to review and approve the company's third-quarter financial performance for FY26. The meeting represents a key milestone in the company's quarterly reporting cycle and regulatory compliance obligations.

Board Meeting Details

The board meeting has been scheduled in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will take place at the company's registered office on Thursday, February 12, 2026.

Key Agenda Items

The board will primarily focus on considering and approving the unaudited standalone financial results for the quarter and nine months ended December 31, 2025. Additionally, the board may address other business matters with the permission of the chairperson during the meeting.

Trading Window Restrictions

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct, Trident Texofab Limited has implemented trading window restrictions for its equity shares. The trading window was closed from January 01, 2026, as part of the company's insider trading prevention measures.

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory requirements and transparency standards. Company Secretary and Compliance Officer Rahul Jariwala has signed the official communication, ensuring proper documentation and compliance with statutory obligations. The notification has been submitted to BSE Limited with the appropriate stock identification details and scrip code information.

Trident Texofab Limited announced robust financial results for the second quarter of fiscal year 2026, with significant top-line growth and margin improvement.

Key Highlights

• Revenue from operations grew 16% year-over-year to ₹3,063.46 lakhs in Q2 FY26
• Total income increased 6% to ₹3,102.56 lakhs
• EBITDA margin expanded substantially to 8.12%, up from -1.04% in Q2 FY25
• Profit after tax rose 12% to ₹112.77 lakhs

Strong Revenue Growth

Trident Texofab continued its growth momentum, with revenue from operations rising 16% compared to the same quarter last year. Total income for Q2 FY26 stood at ₹3,102.56 lakhs, marking a 6% year-over-year increase.

Significant Margin Expansion

The company reported a notable improvement in profitability, with EBITDA margin expanding to 8.12% in Q2 FY26 from -1.04% in Q2 FY25. This 916 basis point increase reflects enhanced operational efficiency.

Manufacturing Focus Drives Growth

Trident Texofab's shift towards manufacturing operations continues to be a key growth driver. The manufacturing division is now the core strength of the company's business, contributing to both revenue growth and margin improvement.

Management Commentary

The management highlighted the company's healthy financial performance, noting revenue growth on both year-over-year and sequential bases. They emphasized the manufacturing division's role as the core strength of operations and expressed satisfaction with the notable improvement in operating profitability margins.

Outlook

With its continued focus on manufacturing and improved operational metrics, Trident Texofab appears well-positioned for future growth. The company's ability to expand margins while growing revenue indicates strengthening fundamentals in its business model.

Investors will likely watch for sustained margin improvement and further growth in the manufacturing segment in coming quarters as indicators of Trident Texofab's long-term prospects.